The U.S. metagenomics market size was exhibited at USD 776.85 million in 2023 and is projected to hit around USD 2,637.07 million by 2033, growing at a CAGR of 13.0% during the forecast period 2024 to 2033.
Report Coverage | Details |
Market Size in 2024 | USD 877.84 Million |
Market Size by 2033 | USD 2,637.07 Million |
Growth Rate From 2024 to 2033 | CAGR of 13.0% |
Base Year | 2023 |
Forecast Period | 2024-2033 |
Segments Covered | Product, Technology, Workflow, Application |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Regional Scope | U.S. |
Key Companies Profiled | Bio-Rad Laboratories, Inc., Illumina, Inc., PerkinElmer, Inc., Thermo Fisher Scientific, Inc., Novogene Co., Ltd., Promega Corporation, QIAGEN, Takara Bio, Inc., Oxford Nanopore Technologies, F. Hoffmann-La Roche Ltd |
This can be attributed to the extensive genomics, oncology, and whole-genome sequencing research. Other factors contributing to adoption of metagenomics technology in U.S. are superior infrastructure for medical and research, generous funding, presence of companies striving for newer technologies for diagnosis and therapies, and skilled and efficient personnel.
U.S. metagenomics market accounted for 38.3% of the global metagenomics market in 2023. The presence of prominent companies, such as Life Technologies, Roche, and Illumina, which significantly contribute to development of rapid and high-throughput sequencing capabilities, has widely promoted market growth. These players are undertaking several strategic initiatives to strengthen their market presence such as R&D activities. For instance, in November 2023, researchers at the University of Cambridge's Milner Therapeutics Institute (MTI) announced studies on functional genomics to explore the role of genetic alterations in the onset & advancement of diseases, aiming to enhance therapies and diagnostics.
Recent technological advancements have significantly contributed to cost-cutting of genome sequencing which has resulted in a notable rise in the prevalence of metagenomic studies, particularly in clinical applications for sequence analysis. Anticipated advancements in DNA technologies & bioinformatics, specifically those streamlining RNA-Seq processes, are poised to contribute further to cost reduction in metagenomics while concurrently improving the accuracy of analysis. As the cost of sequencing continues to decrease, adoption of metagenomics research is rising.
Furthermore, there is a growing trend in microbiome analysis using 16S Ribosomal RNA (rRNA) gene amplicons and shotgun metagenomics. This integrated approach enhances the understanding of microbial communities and their functions. The initiation of high-throughput comparative metagenomics, facilitated by the development of Next-generation Sequencing (NGS) platforms, has triggered a surge in research efforts. These endeavors have significantly advanced our comprehension of the composition & functions of bacterial populations across diverse environments, showcasing the transformative impact of metagenomics in various research domains. Such factors are significantly contributing to market growth.
The kits & reagents segment held the largest share of over 61.53% in 2023. These are designed for specific applications, such as soil, water, and biological sample analysis, and are widely adopted for screening bacteria, viruses, pathogens, fungi, and microeukaryotic species as per the requirement of the study. Introduction of novel kits for library preparation, Polymerase Chain Reaction (PCR) assays, and other assays is expected to boost the growth.
The sequencing & data analytics services segment is expected to show lucrative growth during the forecast period owing to the increased sequencing adoption leading to increased data analysis platform demands. Furthermore, partnerships and collaborations among companies to enhance services such as launch of new platforms, upgrading existing technology & databases to increase knowledge base, and development of novel algorithms & tools for data analysis are expected to accelerate the segment growth.
The shotgun sequencing segment held the largest share of over 30.08% in 2023 owing to its widespread applications in genomics research, clinical diagnostics, and various industries such as environmental monitoring & conservation industry and agriculture & crop improvement industry. Furthermore, with continued technological advancements companies are also focusing on reducing costs, enhancing data analysis capabilities, and promoting standardization.
The 16S sequencing segment is expected to register a considerable CAGR during the forecast period. The growing interest in understanding the human microbiome and microbial communities in diverse environments has driven the demand for techniques like 16S sequencing and metagenomics. Furthermore, advancements in high-throughput technologies and data science make simultaneous leveraging of these data types increasingly feasible. These factors are anticipated to propel segment growth over the forecast period.
The sequencing segment held the largest share of over 53.45% in 2023 owing to platforms such as shotgun sequencing, 16S & ITS ribosomal RNA (rRNA) sequencing kits, and Ion 16S metagenomics kits which are widely used platforms for metagenomics. Technological advancements have lowered the sequencing cost by 28% yearly which has also contributed to the segment’s growth majorly.
The pre-sequencing segment is expected to register a considerable CAGR during the forecast period. This includes sample purification, sample amplification, and library preparation. The process includes the preparation of a template library through fragmentation, DNA tagging, and library enrichment, using microarray & targeted hybridization or RNA library enrichment. All the established companies, such as Illumina, Thermo Fisher Scientific, & Illumina, offer products and solutions for metagenomics workflow and are expected to witness a high demand.
The environmental segment held the largest share of over 25.5% in 2023. Genetic study of microbial communities from environmental samples introduced an entirely new branch of genomics-environmental metagenomics. This segment includes kits & reagents specifically engineered for sample collection, DNA purification, sample enrichment, library preparation, and verification. Moreover, environmental metagenomics analysis is used to study ecological remediation, agricultural microbiome analysis, oceanic oil spills, or other biological investigations.
The clinical diagnostics segment is expected to show lucrative growth during the forecast period. Metagenomics in clinical diagnostics uses advanced genomic technologies to analyze the genetic material of microbial communities in clinical samples. This approach revolutionizes pathogen detection by offering a comprehensive view of diverse pathogens, including bacteria, viruses, fungi, and parasites, overcoming the limitations of traditional diagnostic methods. This is projected to boost the segment growth.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. metagenomics market
Product
Technology
Workflow
Application
Chapter 1. Methodology And Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Product
1.2.2. Technology
1.2.3. Workflow
1.2.4. Application
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives
Chapter 2. U.S. Metagenomics Market: Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Metagenomics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Drivers Analysis
3.2.1.1. Declining expenses of sequencing
3.2.1.2. Development in biotechnology & bioinformatics techniques
3.2.1.3. Rising interest in microbial screening for different investigations
3.2.1.4. Emergence of new fields in genomics that complement metagenomics.
3.2.2. Market Restraint Analysis
3.2.2.1. Limited accessibility to computation and different analytic tools
3.2.2.2. High overall cost of metagenomics
3.3. Industry Analysis Tools
3.3.1. Porter's Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. U.S. Metagenomics Market: Product Business Analysis
4.1. Segment Dashboard
4.2. U.S. Metagenomics Market Product Movement Analysis
4.3. U.S. Metagenomics Market Size & Trend Analysis, by Product, 2021 To 2033
4.3.1. Kits and Reagents
4.3.1.1. Market Estimates And Forecasts 2021 To 2033
4.3.2. Sequencing & Data Analytics Services
4.3.2.1. Market Estimates And Forecasts 2021 To 2033
4.3.3. Software
4.3.3.1. Market Estimates And Forecasts 2021 To 2033
Chapter 5. U.S. Metagenomics Market: Technology Business Analysis
5.1. Segment Dashboard
5.2. U.S. Metagenomics Market Technology Movement Analysis
5.3. U.S. Metagenomics Market Size & Trend Analysis, by Technology, 2021 To 2033
5.3.1. Shotgun Sequencing
5.3.1.1. Market Estimates And Forecasts 2021 To 2033
5.3.2. 16S Sequencing
5.3.2.1. Market Estimates And Forecasts 2021 To 2033
5.3.3. Whole Genome Sequencing
5.3.3.1. Market Estimates And Forecasts 2021 To 2033
5.3.4. Others
5.3.4.1. Market Estimates And Forecasts 2021 To 2033
Chapter 6. U.S. Metagenomics Market: Workflow Business Analysis
6.1. Segment Dashboard
6.2. U.S. Metagenomics Market Workflow Movement Analysis
6.3. U.S. Metagenomics Market Size & Trend Analysis, by Workflow, 2021 To 2033
6.3.1. Pre-sequencing
6.3.1.1. Market Estimates And Forecasts 2021 To 2033
6.3.2. Sequencing
6.3.2.1. Market Estimates And Forecasts 2021 To 2033
6.3.3. Data Analysis
6.3.3.1. Market Estimates And Forecasts 2021 To 2033
Chapter 7. U.S. Metagenomics Market: Application Business Analysis
7.1. Segment Dashboard
7.2. U.S. Metagenomics Market Application Movement Analysis
7.3. U.S. Metagenomics Market Size & Trend Analysis, by Application, 2021 To 2033
7.3.1. Environmental
7.3.1.1. Market Estimates And Forecasts 2021 To 2033
7.3.2. Clinical Diagnostics
7.3.2.1. Market Estimates And Forecasts 2021 To 2033
7.3.3. Drug Discovery
7.3.3.1. Market Estimates And Forecasts 2021 To 2033
7.3.4. Biotechnology
7.3.4.1. Market Estimates And Forecasts 2021 To 2033
7.3.5. Food & nutrition
7.3.5.1. Market Estimates And Forecasts 2021 To 2033
7.3.6. Others
7.3.6.1. Market Estimates And Forecasts 2021 To 2033
Chapter 8. Competitive Landscape
8.1. Participant Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2023
8.4. Participant’s Overview
8.4.1. Bio-Rad Laboratories, Inc.
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Illumina, Inc.
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. PerkinElmer, Inc
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Thermo Fisher Scientific, Inc
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Novogene Co., Ltd.
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Promega Corporation
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. QIAGEN
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Takara Bio, Inc.
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Oxford Nanopore Technologies plc.
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. F. Hoffmann-La Roche Ltd.
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives